Title [MINIREVIEW]The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
Author Sandrine M. Soh1, Yeongjun Kim1, Chanwoo Kim1, Ui Soon Jang1, and Hye-Ra Lee1,2*
Address 1Department of Biotechnology and Bioinformatics, College of Science and Technology, Korea University, Sejong 30019, Republic of Korea, 2Department of Lab Medicine, College of Medicine, Korea University, Seoul 02841, Republic of Korea
Bibliography Journal of Microbiology, 59(9),807-818, 2021,
DOI 10.1007/s12275-021-1348-5
Key Words SARS-CoV-2, transmission, vaccine, neutralization, monoclonal antibodies, variants
Abstract The causative factor of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating. Interestingly, identified mutations mainly occur in the spike (S) protein which interacts with the ACE2 receptor and is cleaved via serine protease TMPRSS2. Some mutated strains are becoming dominant in various parts of the globe because of increased transmissibility as well as cell entry efficacy. Remarkably, the neutralizing activity of monoclonal antibodies, convalescent sera, and vaccines against the variants has been reported to be significantly reduced. Therefore, the efficacy of various monoclonal antibodies therapy and vaccines against these variants is becoming a great global concern. We herein summarize the current status of SARS-CoV- 2 with gears shifted towards the recent and most common genetic variants in relation to transmission, neutralizing activity, and vaccine efficacy.